The Asia-Pacific Dengue Prevention Board organized a meeting (Kuala Lumpur, Malaysia, 1–2 June 2016) to highlight points for consideration about CYD-TDV vaccine introduction and to define the most useful tools and approaches for dengue endemic countries to develop policies.
We invite you to read the full report on the "Development of Dengue Vaccines: Issues relating to dengue vaccine introduction in light of the WHO SAGE recommendations" here.
The Dengue Vaccine Initiative is a consortium of four organizations, each of which brings essential and complementary capabilities to the project.
The International Vaccine Institute will lead the Consortium and have lead responsibility for the field studies under the Evidence for Decision-Making component of DVI and for preparation of the focal country vaccine introduction cases and the global investment case. IVI is an international organization based in Seoul, Korea, established under treaty, with 40 countries and the WHO as signatories to its charter. IVI’s mission is “to combat infectious diseases through innovations in vaccine design, development and introduction, addressing the needs of people in developing countries”.
The WHO Initiative for Vaccine Research (IVR) will have the lead role in the development of information and guidance documents, and in regulatory training activities. The unit’s mission is to accelerate the development and optimal use of safe and effective vaccines and technologies, especially in developing countries. IVR has expertise in the fields of product R&D, vaccine manufacturing and regulation, vaccine clinical trials, vaccine introduction, and cost-effectiveness analysis.
The International Vaccine Access Center (of the Johns Hopkins University Bloomberg School of Public Health) will lead activities related to the financing of dengue vaccine purchase including budget impact analysis and strategic demand forecasting. It will also provide high level support to WHO on regulatory pathways. The mission of IVAC is to accelerate global access to life-saving vaccines through development and implementation of evidence-based policies.
The Sabin Vaccine Institute, a non-profit organization established in 1994 and headquartered in Washington, DC, will have the lead role in the DVI’s coalition-building, advocacy and communications activities. Sabin’s mission is to save lives by stimulating the development of new vaccines against vaccine preventable and neglected tropical diseases, and by advocating for improved access to vaccines and essential medicines for people throughout the world. Sabin has established coalitions to raise awareness of important diseases among policymakers and to mobilize funds to combat these diseases through vaccination or other effective prevention and treatment efforts.